## Phylogeny  
• PIK3CG encodes p110γ, the sole catalytic subunit of class IB phosphoinositide-3-kinases within the PI3K clade of the human kinome described by Manning et al. and reviewed in later work (wymann2003phosphoinositide3kinasesignalling pages 1-2).  
• The kinase domain shares ~35 % identity with the class IA isoform p110β, indicating close evolutionary relatedness inside class I PI3Ks (nurnberg2019functionregulationand pages 3-5).  
• Orthologous genes are documented in Mus musculus, Rattus norvegicus, Danio rerio, Drosophila melanogaster and Caenorhabditis elegans, illustrating conservation from vertebrates to invertebrates (lanahan2022theroleof pages 8-9, wymann2003phosphoinositide3kinasesignalling pages 1-2).  

## Reaction Catalyzed  
ATP + PI(4,5)P₂ ⇌ ADP + PI(3,4,5)P₃ + H⁺ (nurnberg2019functionregulationand pages 1-3, lanahan2022theroleof pages 1-4).  

## Cofactor Requirements  
Catalysis requires Mg²⁺ ions (nurnberg2019functionregulationand pages 23-25).  

## Substrate Specificity  
• Primary lipid substrate: phosphatidylinositol-4,5-bisphosphate located on the inner plasma-membrane leaflet (nurnberg2019functionregulationand pages 17-18).  
• No reproducible consensus motif has been reported for protein substrates; the intrinsic protein-kinase activity is weak and not sequence-defined (nurnberg2019functionregulationand pages 8-9).  

## Structure  
• Full length: 1-102 aa arranged in five ordered modules (nurnberg2019functionregulationand pages 1-3, gu2024developmentofpi3kγ pages 1-2):  
  – ABD-like region, residues 1–108, lacks p85 binding.  
  – Ras-binding domain (RBD), residues 220–311, engages GTP-loaded Ras (gu2024developmentofpi3kγ pages 1-2).  
  – C2 domain, residues 312–480, mediates membrane association.  
  – Helical domain, residues 481–685, hub for adaptor and Gβγ contacts; houses regulatory Ser502/Ser582 (nurnberg2019functionregulationand pages 3-5).  
  – Bilobal kinase domain, residues 686–1102, contains the ATP pocket, αC helix and activation loop (qiu2019recentdiscoveryof pages 1-3).  
• Catalytic pocket: Lys833, Tyr867 and Val882 line the adenine site; Glu814, Gly829 and Ala885 form an isoform-specific semi-hydrophobic cleft exploited by selective inhibitors (qiu2019recentdiscoveryof pages 1-3, qiu2019recentdiscoveryof pages 14-16).  
• Active-state crystal structures of human p110γ/p101 complexes (PDB 6AUD, 6XRM) reveal outward rotation of helix kα12, generating a membrane-interactive surface (gu2024developmentofpi3kγ pages 1-2, gangadhara2019aclassof pages 29-29).  
• Adaptor interfaces: p101/p84 bind the RBD-C2 linker and helical domain, while a basic 552-RK motif in the C2-helical linker contacts Gβγ (vadas2013moleculardeterminantsof pages 2-2).  
• Ras-GTP bridges the RBD and a surface on the kinase C-lobe, with eleven RBD residues (F221, K223, T228, etc.) contacting switch I/II of Ras (unknownauthors2022characterizationofras pages 25-29).  

## Regulation  
Post-translational modifications  
• Ser502 in the helical domain is phosphorylated by PKCβ, weakening p87 binding and promoting complex dissociation (nurnberg2019functionregulationand pages 3-5).  
• Ser582 (helical domain) is phosphorylated by PKCβ, doubles lipid-kinase activity and expels p84, releasing the enzyme from GPCR control (walser2013pkcβphosphorylatespi3kγ pages 10-11).  
• Thr1024 in the kinase domain is phosphorylated by PKA, producing negative feedback in β-adrenergic signalling (walser2013pkcβphosphorylatespi3kγ pages 10-11).  
• Ser1101 undergoes autophosphorylation with minimal catalytic impact (nurnberg2019functionregulationand pages 8-9).  

Allosteric control  
• Gβγ dimers bind the helical domain and regulatory subunits, providing potent allosteric activation; p101 confers high-affinity sensitivity, whereas p87 yields weaker stimulation (nurnberg2019functionregulationand pages 3-5).  
• Ras-GTP synergises with Gβγ by engaging the RBD, enhancing membrane recruitment and catalytic turnover (unknownauthors2022characterizationofras pages 25-29).  

## Function  
Expression  
• High in leukocytes (neutrophils, macrophages, dendritic cells, mast cells, T and B lymphocytes) and detectable in cardiomyocytes, endothelial cells, CNS, kidney, pancreas and prostate (lanahan2022theroleof pages 1-4, nurnberg2019functionregulationand pages 3-5).  

Upstream regulators  
• GPCR agonists → Gβγ dimers (nurnberg2019functionregulationand pages 3-5).  
• Small GTPases Ras and Rab8a (nurnberg2019functionregulationand pages 8-9).  
• TLRs and cytokine receptors via p101-mediated recruitment (lanahan2022theroleof pages 4-8).  

Downstream effectors and interactors  
• Generates PIP3 that recruits AKT, PDPK1 and mTOR components (nurnberg2019functionregulationand pages 11-13).  
• Forms complexes with PDE3B/PDE4B and PKA regulatory subunits to organise cAMP nanodomains (nurnberg2019functionregulationand pages 9-11).  
• Associates with GRK2 and β-arrestins in β-adrenergic receptor regulation (nurnberg2019functionregulationand pages 13-15).  

Physiological roles  
• Directs chemotaxis of neutrophils, dendritic cells, NK cells and T-lymphocytes (nurnberg2019functionregulationand pages 11-13, lanahan2022theroleof pages 4-8).  
• Controls ROS production in neutrophils and degranulation in mast cells (nurnberg2019functionregulationand pages 11-13).  
• Reprogrammes tumour-associated macrophages, aiding immunotherapy efficacy (gu2024developmentofpi3kγ pages 8-9).  
• Modulates β-adrenergic signalling in heart and vascular tone through kinase-dependent and scaffold mechanisms (nurnberg2019functionregulationand pages 13-15).  
• Regulates nociception and synaptic plasticity via cAMP compartmentalisation (nurnberg2019functionregulationand pages 15-17).  

## Inhibitors  
• Pan-PI3K: Wortmannin and LY294002 (nurnberg2019functionregulationand pages 17-18).  
• PI3Kγ-selective: AS-605240, IC₅₀ 8 nM (qiu2019recentdiscoveryof pages 14-16); CZC24832, Kd 19 nM (bergamini2012aselectiveinhibitor pages 3-4).  
• Clinical-stage: IPI-549 (Eganelisib), IC₅₀ 16 nM, >200-fold isoform selectivity (evans2016discoveryofa pages 7-8).  
• Dual PI3Kδ/γ: TG100-115 under cardiovascular evaluation (unknownauthors2011discoveryanddevelopment pages 66-72).  
• Active-state binders exploiting kα12 displacement: AZ2 and AZ3 (gangadhara2019aclassof pages 29-29).  
• Additional isoform-selective series include N-alkyl isoindolinones, thiazolopiperidines and 7-azaindoles guided by the semi-hydrophobic cleft (gu2024developmentofpi3kγ pages 10-10).  

## Other Comments  
• Bi-allelic loss-of-function mutations cause inactivated PI3K-γ syndrome with antibody deficiency, cytopenias, pneumonitis and colitis (takeda2019humanpi3kγdeficiency pages 1-2).  
• Over-expression of p101 is oncogenic, whereas phosphorylated p87 may act as a tumour suppressor, indicating regulatory-subunit imbalance in cancer (nurnberg2019functionregulationand pages 15-17).  
• RBD mutation Val282Ala disrupts Ras binding and associates with chronic infection phenotypes (nurnberg2019functionregulationand pages 8-9).  
• PI3Kγ signalling contributes to hypertension, atherosclerosis, pancreatic and prostate cancers, and heart-failure pathology (nurnberg2019functionregulationand pages 13-15, lanahan2022theroleof pages 8-9).

References

1. (gu2024developmentofpi3kγ pages 1-2): Dong-yan Gu, Meng-meng Zhang, Jia Li, Yu-bo Zhou, and Rong Sheng. Development of pi3kγ selective inhibitors: the strategies and application. Acta Pharmacologica Sinica, 45:238-247, Oct 2024. URL: https://doi.org/10.1038/s41401-023-01166-8, doi:10.1038/s41401-023-01166-8. This article has 5 citations and is from a peer-reviewed journal.

2. (lanahan2022theroleof pages 4-8): Stephen M. Lanahan, Matthias P. Wymann, and Carrie L. Lucas. The role of pi3kγ in the immune system: new insights and translational implications. Nature Reviews Immunology, 22:687-700, Mar 2022. URL: https://doi.org/10.1038/s41577-022-00701-8, doi:10.1038/s41577-022-00701-8. This article has 56 citations and is from a highest quality peer-reviewed journal.

3. (lanahan2022theroleof pages 8-9): Stephen M. Lanahan, Matthias P. Wymann, and Carrie L. Lucas. The role of pi3kγ in the immune system: new insights and translational implications. Nature Reviews Immunology, 22:687-700, Mar 2022. URL: https://doi.org/10.1038/s41577-022-00701-8, doi:10.1038/s41577-022-00701-8. This article has 56 citations and is from a highest quality peer-reviewed journal.

4. (nurnberg2019functionregulationand pages 11-13): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

5. (nurnberg2019functionregulationand pages 15-17): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

6. (nurnberg2019functionregulationand pages 17-18): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

7. (nurnberg2019functionregulationand pages 23-25): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

8. (nurnberg2019functionregulationand pages 3-5): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

9. (nurnberg2019functionregulationand pages 8-9): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

10. (nurnberg2019functionregulationand pages 9-11): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

11. (qiu2019recentdiscoveryof pages 14-16): Xiaqiu Qiu, Yucheng Tian, Zhuangzhuang Liang, Yujie Sun, Zhiyu Li, and Jinlei Bian. Recent discovery of phosphoinositide 3-kinase γ inhibitors for the treatment of immune diseases and cancers. Future medicinal chemistry, 11 16:2151-2169, Sep 2019. URL: https://doi.org/10.4155/fmc-2019-0010, doi:10.4155/fmc-2019-0010. This article has 21 citations and is from a peer-reviewed journal.

12. (walser2013pkcβphosphorylatespi3kγ pages 10-11): Romy Walser, John E. Burke, Elena Gogvadze, Thomas Bohnacker, Xuxiao Zhang, Daniel Hess, Peter Küenzi, Michael Leitges, Emilio Hirsch, Roger L. Williams, Muriel Laffargue, and Matthias P. Wymann. Pkcβ phosphorylates pi3kγ to activate it and release it from gpcr control. PLoS Biology, 11:e1001587, Jun 2013. URL: https://doi.org/10.1371/journal.pbio.1001587, doi:10.1371/journal.pbio.1001587. This article has 63 citations and is from a highest quality peer-reviewed journal.

13. (gangadhara2019aclassof pages 29-29): Gangadhara Gangadhara, Göran Dahl, Thomas Bohnacker, Rebecca Rae, Jenny Gunnarsson, Stefan Blaho, Linda Öster, Helena Lindmark, Kostas Karabelas, Nils Pemberton, Christian Tyrchan, Mickael Mogemark, Matthias P. Wymann, Roger L. Williams, Matthew W. D. Perry, Tineke Papavoine, and Jens Petersen. A class of highly selective inhibitors bind to an active state of pi3kγ. Nature Chemical Biology, 15:348-357, Feb 2019. URL: https://doi.org/10.1038/s41589-018-0215-0, doi:10.1038/s41589-018-0215-0. This article has 57 citations and is from a highest quality peer-reviewed journal.

14. (gu2024developmentofpi3kγ pages 8-9): Dong-yan Gu, Meng-meng Zhang, Jia Li, Yu-bo Zhou, and Rong Sheng. Development of pi3kγ selective inhibitors: the strategies and application. Acta Pharmacologica Sinica, 45:238-247, Oct 2024. URL: https://doi.org/10.1038/s41401-023-01166-8, doi:10.1038/s41401-023-01166-8. This article has 5 citations and is from a peer-reviewed journal.

15. (lanahan2022theroleof pages 1-4): Stephen M. Lanahan, Matthias P. Wymann, and Carrie L. Lucas. The role of pi3kγ in the immune system: new insights and translational implications. Nature Reviews Immunology, 22:687-700, Mar 2022. URL: https://doi.org/10.1038/s41577-022-00701-8, doi:10.1038/s41577-022-00701-8. This article has 56 citations and is from a highest quality peer-reviewed journal.

16. (nurnberg2019functionregulationand pages 1-3): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

17. (nurnberg2019functionregulationand pages 13-15): Bernd Nürnberg and Sandra Beer-Hammer. Function, regulation and biological roles of pi3kγ variants. Biomolecules, 9:427, Aug 2019. URL: https://doi.org/10.3390/biom9090427, doi:10.3390/biom9090427. This article has 49 citations and is from a peer-reviewed journal.

18. (qiu2019recentdiscoveryof pages 1-3): Xiaqiu Qiu, Yucheng Tian, Zhuangzhuang Liang, Yujie Sun, Zhiyu Li, and Jinlei Bian. Recent discovery of phosphoinositide 3-kinase γ inhibitors for the treatment of immune diseases and cancers. Future medicinal chemistry, 11 16:2151-2169, Sep 2019. URL: https://doi.org/10.4155/fmc-2019-0010, doi:10.4155/fmc-2019-0010. This article has 21 citations and is from a peer-reviewed journal.

19. (takeda2019humanpi3kγdeficiency pages 1-2): Andrew J. Takeda, Timothy J. Maher, Yu Zhang, Stephen M. Lanahan, Molly L. Bucklin, Susan R. Compton, Paul M. Tyler, William A. Comrie, Makoto Matsuda, Kenneth N. Olivier, Stefania Pittaluga, Joshua J. McElwee, Debra A. Long Priel, Douglas B. Kuhns, Roger L. Williams, Peter J. Mustillo, Matthias P. Wymann, V. Koneti Rao, and Carrie L. Lucas. Human pi3kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nature Communications, Sep 2019. URL: https://doi.org/10.1038/s41467-019-12311-5, doi:10.1038/s41467-019-12311-5. This article has 74 citations and is from a highest quality peer-reviewed journal.

20. (unknownauthors2011discoveryanddevelopment pages 66-72): Discovery and development of dual PI3Kδ/γ inhibitors for use as novel anti-inflammatory agents

21. (unknownauthors2022characterizationofras pages 25-29): Characterization of RAS Interactions with PI3K

22. (vadas2013moleculardeterminantsof pages 2-2): Oscar Vadas, Hashem A. Dbouk, Aliaksei Shymanets, Olga Perisic, John E. Burke, Widian F. Abi Saab, Bassem D. Khalil, Christian Harteneck, Anne R. Bresnick, Bernd Nürnberg, Jonathan M. Backer, and Roger L. Williams. Molecular determinants of pi3kγ-mediated activation downstream of g-protein–coupled receptors (gpcrs). Proceedings of the National Academy of Sciences, 110:18862-18867, Nov 2013. URL: https://doi.org/10.1073/pnas.1304801110, doi:10.1073/pnas.1304801110. This article has 121 citations.

23. (wymann2003phosphoinositide3kinasesignalling pages 1-2): Matthias P Wymann, Marketa Zvelebil, and Muriel Laffargue. Phosphoinositide 3-kinase signalling – which way to target? Trends in Pharmacological Sciences, 24:366-376, Jul 2003. URL: https://doi.org/10.1016/s0165-6147(03)00163-9, doi:10.1016/s0165-6147(03)00163-9. This article has 450 citations and is from a highest quality peer-reviewed journal.

24. (bergamini2012aselectiveinhibitor pages 3-4): Giovanna Bergamini, Kathryn Bell, Satoko Shimamura, Thilo Werner, Andrew Cansfield, Katrin Müller, Jessica Perrin, Christina Rau, Katie Ellard, Carsten Hopf, Carola Doce, Daniel Leggate, Raffaella Mangano, Toby Mathieson, Alison O'Mahony, Ivan Plavec, Faiza Rharbaoui, Friedrich Reinhard, Mikhail M Savitski, Nigel Ramsden, Emilio Hirsch, Gerard Drewes, Oliver Rausch, Marcus Bantscheff, and Gitte Neubauer. A selective inhibitor reveals pi3kγ dependence of t(h)17 cell differentiation. Nature chemical biology, 8 6:576-82, Jun 2012. URL: https://doi.org/10.1038/nchembio.957, doi:10.1038/nchembio.957. This article has 137 citations and is from a highest quality peer-reviewed journal.

25. (evans2016discoveryofa pages 7-8): Catherine A. Evans, Tao Liu, André Lescarbeau, Somarajan J. Nair, Louis Grenier, Johan A. Pradeilles, Quentin Glenadel, Thomas Tibbitts, Ann M. Rowley, Jonathan P. DiNitto, Erin E. Brophy, Erin L. O’Hearn, Janid A. Ali, David G. Winkler, Stanley I. Goldstein, Patrick O’Hearn, Christian M. Martin, Jennifer G. Hoyt, John R. Soglia, Culver Cheung, Melissa M. Pink, Jennifer L. Proctor, Vito J. Palombella, Martin R. Tremblay, and Alfredo C. Castro. Discovery of a selective phosphoinositide-3-kinase (pi3k)-γ inhibitor (ipi-549) as an immuno-oncology clinical candidate. ACS Medicinal Chemistry Letters, 7:862-867, Aug 2016. URL: https://doi.org/10.1021/acsmedchemlett.6b00238, doi:10.1021/acsmedchemlett.6b00238. This article has 130 citations and is from a peer-reviewed journal.

26. (gu2024developmentofpi3kγ pages 10-10): Dong-yan Gu, Meng-meng Zhang, Jia Li, Yu-bo Zhou, and Rong Sheng. Development of pi3kγ selective inhibitors: the strategies and application. Acta Pharmacologica Sinica, 45:238-247, Oct 2024. URL: https://doi.org/10.1038/s41401-023-01166-8, doi:10.1038/s41401-023-01166-8. This article has 5 citations and is from a peer-reviewed journal.
